Molecular Profiling in Non-Squamous Non-Small Cell Lung Carcinoma: Towards a Switch to Next-Generation Sequencing Reflex Testing

Overview

Journal J Pers Med

Date 2022 Oct 27

PMID 36294823

Authors

Nina Pujol

Simon Heeke

Christophe Bontoux

Jacques Boutros

Marius Ilie

Veronique Hofman

Charles-Hugo Marquette

Paul Hofman

Jonathan Benzaquen

Affiliations

Soon will be listed here.

Abstract

Molecular diagnosis of lung cancer is a constantly evolving field thanks to major advances in precision oncology. The wide range of actionable molecular alterations in non-squamous non-small cell lung carcinoma (NS-NSCLC) and the multiplicity of mechanisms of resistance to treatment resulted in the need for repeated testing to establish an accurate molecular diagnosis, as well as to track disease evolution over time. While assessing the increasing complexity of the molecular composition of tumors at baseline, as well as over time, has become increasingly challenging, the emergence and implementation of next-generation sequencing (NGS) testing has extensively facilitated molecular profiling in NS-NSCLC. In this review, we discuss recent developments in the molecular profiling of NS-NSCLC and how NGS addresses current needs, as well as how it can be implemented to address future challenges in the management of NS-NSCLC.

Citing Articles

Lung Cancer Therapy: The Role of Personalized Medicine.

Ramos R, Moura C, Costa M, Lamas N, Correia R, Garcez D Cancers (Basel). 2025; 17(5).

PMID: 40075573 PMC: 11899562. DOI: 10.3390/cancers17050725.

The Detailed Analysis of Polish Patients with Non-Small Cell Lung Cancer Through Insights from Molecular Testing (POL-MOL Study).

Kowalski D, Zaborowska-Szmit M, Bryl M, Byszek A, Dziedzic D, Jaskiewicz P Int J Mol Sci. 2024; 25(21).

PMID: 39518907 PMC: 11547071. DOI: 10.3390/ijms252111354.

Advancing Cancer Care in Colombia: Results of the First In Situ Implementation of Comprehensive Genomic Profiling.

Lopez Rivera J, Rueda-Gaitan P, Rios Pinto L, Rodriguez Gutierrez D, Gomez-Lopera N, Lamilla J J Pers Med. 2024; 14(9).

PMID: 39338229 PMC: 11433056. DOI: 10.3390/jpm14090975.

Enhancing Lung Cancer Care in Portugal: Bridging Gaps for Improved Patient Outcomes.

Ramos R, Moura C, Costa M, Lamas N, Correia R, Garcez D J Pers Med. 2024; 14(5).

PMID: 38793028 PMC: 11121920. DOI: 10.3390/jpm14050446.

Actionable mutational profiling in solid tumors using hybrid-capture-based next-generation sequencing in a real-world setting in Spain.

Zazo S, Perez-Buira S, Carvajal N, Plaza-Sanchez J, Manso R, Perez-Gonzalez N Cancer Med. 2024; 13(3):e6827.

PMID: 38213074 PMC: 10905216. DOI: 10.1002/cam4.6827.

References

Verdaguer H, Sauri T, Acosta D, Guardiola M, Sierra A, Hernando J . ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma. Clin Cancer Res. 2022; 28(8):1662-1671. DOI: 10.1158/1078-0432.CCR-21-2384. View

Schluckebier L, Caetano R, Garay O, Montenegro G, Custodio M, Aran V . Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients. BMC Cancer. 2020; 20(1):875. PMC: 7489015. DOI: 10.1186/s12885-020-07240-2. View

Adizie J, Tweedie J, Khakwani A, Peach E, Hubbard R, Wood N . Biomarker Testing for People With Advanced Lung Cancer in England. JTO Clin Res Rep. 2021; 2(6):100176. PMC: 8474239. DOI: 10.1016/j.jtocrr.2021.100176. View

Steuten L, Goulart B, Meropol N, Pritchard D, Ramsey S . Cost Effectiveness of Multigene Panel Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer. JCO Clin Cancer Inform. 2019; 3:1-10. DOI: 10.1200/CCI.19.00002. View

Jorgensen J, Mollerup J . Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC. Cancers (Basel). 2022; 14(9). PMC: 9105764. DOI: 10.3390/cancers14092150. View

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

Mino-Kenudson M, Chirieac L, Law K, Hornick J, Lindeman N, Mark E . A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 2010; 16(5):1561-71. PMC: 2831135. DOI: 10.1158/1078-0432.CCR-09-2845. View

Smolle E, Pichler M . Non-Smoking-Associated Lung Cancer: A distinct Entity in Terms of Tumor Biology, Patient Characteristics and Impact of Hereditary Cancer Predisposition. Cancers (Basel). 2019; 11(2). PMC: 6406530. DOI: 10.3390/cancers11020204. View

Griesinger F, Eberhardt W, Nusch A, Reiser M, Zahn M, Maintz C . Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). Lung Cancer. 2020; 152:174-184. DOI: 10.1016/j.lungcan.2020.10.012. View

10.

Hofman P, Rouleau E, Sabourin J, Denis M, Deleuze J, Barlesi F . Predictive molecular pathology in non-small cell lung cancer in France: The past, the present and the perspectives. Cancer Cytopathol. 2020; 128(9):601-610. DOI: 10.1002/cncy.22318. View

11.

Horgan D, Curigliano G, Riess O, Hofman P, Buttner R, Conte P . Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe. J Pers Med. 2022; 12(1). PMC: 8780351. DOI: 10.3390/jpm12010072. View

12.

Ju Y, Lee W, Shin J, Lee S, Bleazard T, Won J . A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 2011; 22(3):436-45. PMC: 3290779. DOI: 10.1101/gr.133645.111. View

13.

Sholl L, Aisner D, Varella-Garcia M, Berry L, Dias-Santagata D, Wistuba I . Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2015; 10(5):768-777. PMC: 4410843. DOI: 10.1097/JTO.0000000000000516. View

14.

Gow C, Hsieh M, Lin Y, Liu Y, Shih J . Validation of Immunohistochemistry for the Detection of V600E-Mutated Lung Adenocarcinomas. Cancers (Basel). 2019; 11(6). PMC: 6627826. DOI: 10.3390/cancers11060866. View

15.

Heitzer E, van den Broek D, Denis M, Hofman P, Hubank M, Mouliere F . Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer. ESMO Open. 2022; 7(2):100399. PMC: 8867049. DOI: 10.1016/j.esmoop.2022.100399. View

16.

Rolfo C, Mack P, Scagliotti G, Aggarwal C, Arcila M, Barlesi F . Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021; 16(10):1647-1662. DOI: 10.1016/j.jtho.2021.06.017. View

17.

Lin H, Yin Y, Crossland V, Wu Y, Ou S . Testing Patterns and Detection of Exon 20 Insertions in the United States. JTO Clin Res Rep. 2022; 3(3):100285. PMC: 8851244. DOI: 10.1016/j.jtocrr.2022.100285. View

18.

Xia P, Zhang L, Li P, Liu E, Li W, Zhang J . Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers. J Transl Med. 2021; 19(1):308. PMC: 8283930. DOI: 10.1186/s12967-021-02982-4. View

19.

Mendelsohn J, Baselga J . Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003; 21(14):2787-99. DOI: 10.1200/JCO.2003.01.504. View

20.

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View